[MATRIX] QoQ Annualized Quarter Result on 31-Dec-2022 [#3]

Stock
[MATRIX] MATRIX CONCEPTS HOLDINGS BHD
Announcement Date
28-Feb-2023
Admission Sponsor
-
Sponsor
-
Financial Year
31-Mar-2023
Quarter
31-Dec-2022 [#3]
Profit Trend
QoQ- 3.81%
YoY- 5.58%
Quarter Report
Latest QR
Upcoming QR
MATRIX's Result
MATRIX's Financial Summary
View:
Show?
Annualized Quarter Result
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
Revenue 1,381,560 1,325,704 1,117,624 1,087,221 903,212 917,024 886,818 34.35%
PBT 342,070 348,888 273,290 271,756 260,690 255,248 270,657 16.87%
Tax -88,448 -94,072 -69,160 -72,336 -68,852 -70,472 -70,000 16.85%
NP 253,622 254,816 204,130 199,420 191,838 184,776 200,657 16.88%
-
NP to SH 257,264 258,408 208,535 202,638 195,210 188,152 205,022 16.32%
-
Tax Rate 25.86% 26.96% 25.31% 26.62% 26.41% 27.61% 25.86% -
Total Cost 1,127,938 1,070,888 913,494 887,801 711,374 732,248 686,161 39.24%
-
Net Worth 2,064,725 2,027,184 1,989,644 1,952,103 1,349,279 1,910,392 1,902,049 5.61%
Dividend
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
Div 125,134 125,134 115,749 116,792 87,050 100,107 104,279 12.91%
Div Payout % 48.64% 48.43% 55.51% 57.64% 44.59% 53.21% 50.86% -
Equity
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
Net Worth 2,064,725 2,027,184 1,989,644 1,952,103 1,349,279 1,910,392 1,902,049 5.61%
NOSH 1,251,348 1,251,348 1,251,348 1,251,348 1,251,348 834,232 834,232 31.00%
Ratio Analysis
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
NP Margin 18.36% 19.22% 18.26% 18.34% 21.24% 20.15% 22.63% -
ROE 12.46% 12.75% 10.48% 10.38% 14.47% 9.85% 10.78% -
Per Share
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
RPS 110.41 105.94 89.31 86.88 103.76 109.92 106.30 2.55%
EPS 20.56 20.64 16.66 16.20 22.90 22.56 24.58 -11.21%
DPS 10.00 10.00 9.25 9.33 10.00 12.00 12.50 -13.81%
NAPS 1.65 1.62 1.59 1.56 1.55 2.29 2.28 -19.37%
Adjusted Per Share Value based on latest NOSH - 1,251,348
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
RPS 110.41 105.94 89.31 86.88 72.18 73.28 70.87 34.35%
EPS 20.56 20.64 16.66 16.20 15.60 15.04 16.38 16.34%
DPS 10.00 10.00 9.25 9.33 6.96 8.00 8.33 12.94%
NAPS 1.65 1.62 1.59 1.56 1.0783 1.5267 1.52 5.61%
Price Multiplier on Financial Quarter End Date
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
Date 29/09/23 30/06/23 31/03/23 30/12/22 30/09/22 30/06/22 31/03/22 -
Price 1.49 1.41 1.45 1.47 1.44 2.36 2.37 -
P/RPS 1.35 1.33 1.62 1.69 1.39 2.15 2.23 -28.41%
P/EPS 7.25 6.83 8.70 9.08 6.42 10.46 9.64 -17.28%
EY 13.80 14.65 11.49 11.02 15.57 9.56 10.37 20.96%
DY 6.71 7.09 6.38 6.35 6.94 5.08 5.27 17.45%
P/NAPS 0.90 0.87 0.91 0.94 0.93 1.03 1.04 -9.18%
Price Multiplier on Announcement Date
30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 CAGR
Date 23/11/23 22/08/23 24/05/23 28/02/23 23/11/22 23/08/22 25/05/22 -
Price 1.61 1.47 1.43 1.49 1.47 2.29 2.43 -
P/RPS 1.46 1.39 1.60 1.71 1.42 2.08 2.29 -25.90%
P/EPS 7.83 7.12 8.58 9.20 6.56 10.15 9.89 -14.40%
EY 12.77 14.05 11.65 10.87 15.26 9.85 10.11 16.83%
DY 6.21 6.80 6.47 6.26 6.80 5.24 5.14 13.42%
P/NAPS 0.98 0.91 0.90 0.96 0.95 1.00 1.07 -5.68%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment